Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

<p>Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?</p><p><br></p><p>In this week’s episode of The Weekly Dose, I dig into Novo’s long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txt</p><p><br></p><p>We also break down Pfizer’s decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer’s remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly’s obesity-fueled rally and asking just how big this market can get.</p><p><br></p><p>In this episode:</p><p><br></p><p>00:00 Novo’s synthetic semaglutide problem</p><p>02:00 VoaFit sponsor message</p><p>03:30 The 16-month-old On The Pen receipt</p><p>05:00 Recombinant vs. synthetic semaglutide</p><p>07:00 Novo’s FDA, legal, and political strategy</p><p>09:00 Pfizer kills two obesity drugs</p><p>11:00 What happened to Metsera’s oral pipeline?</p><p>13:00 The GIP agonist vs. antagonist paradox</p><p>15:00 Why China matters to Pfizer and Novo</p><p>17:00 Could Novo eventually make synthetic semaglutide?</p><p>18:30 What comes next for Lilly, Novo, and Pfizer</p><p><br></p><p>The big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?</p><p><br></p><p>Comment below. I want to know where you land.</p><p><br></p><p>More obesity medicine news and analysis: OnThePen.com</p><p><br></p><p>All my links, socials, and resources: linktr.ee/manonthemounjaro</p><p><br></p><p>This episode is sponsored by VoaFit. Learn more at voafit.com/otp.</p><p><br></p><p>#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera</p>